MaxCyte Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MaxCyte stock.
View analyst ratings for MaxCyte or view top-rated stocks.

MaxCyte's stock was trading at $6.43 at the start of the year. Since then, MXCT shares have decreased by 24.9% and is now trading at $4.83.
View the best growth stocks for 2022 here.

MaxCyte is scheduled to release its next quarterly earnings announcement on Monday, September 12th 2022.
View our earnings forecast for MaxCyte.

MaxCyte, Inc. (NASDAQ:MXCT) posted its quarterly earnings results on Monday, May, 9th. The company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.03. The company earned $11.59 million during the quarter, compared to the consensus estimate of $11 million. MaxCyte had a negative net margin of 41.15% and a negative trailing twelve-month return on equity of 7.39%.
View MaxCyte's earnings history.

MaxCyte issued an update on its first quarter 2022 earnings guidance on Tuesday, April, 26th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $11 M-, compared to the consensus revenue estimate of $8.46 million.

Some companies that are related to MaxCyte include National Research (NRC), SomaLogic (SLGC), Absci (ABSI), Avista Public Acquisition Corp. II (AHPA), Inotiv (NOTV), Science 37 (SNCE), Starpharma (SPHRY), Luna Innovations (LUNA), Zymergen (ZY), Bioqual (BIOQ), Auxly Cannabis Group (CBWTF), ProMIS Neurosciences (ARFXF), AIkido Pharma (AIKI), Inhibitor Therapeutics (INTI) and HedgePath Pharmaceuticals (HPPI).
View all of MXCT's competitors.

(MXCT) raised $150 million in an initial public offering on Friday, July 30th 2021. The company issued 12,000,000 shares at $11.50-$13.50 per share.

MaxCyte trades on the NASDAQ under the ticker symbol "MXCT."

MaxCyte's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.36%), Vitruvian Partners LLP (4.32%), Vanguard Group Inc. (3.23%), River & Mercantile Asset Management LLP (2.07%), Massachusetts Financial Services Co. MA (1.84%) and American Century Companies Inc. (1.63%).

MXCT stock was sold by a variety of institutional investors in the last quarter, including Montanaro Asset Management Ltd, River & Mercantile Asset Management LLP, Nicholas Investment Partners LP, RTW Investments LP, Royce & Associates LP, Apis Capital Advisors LLC, TD Asset Management Inc., and Bank of New York Mellon Corp.

MXCT stock was purchased by a variety of institutional investors in the last quarter, including American Century Companies Inc., Vitruvian Partners LLP, Goldman Sachs Group Inc., Grandeur Peak Global Advisors LLC, State Street Corp, BlackRock Inc., Vanguard Group Inc., and First Light Asset Management LLC.

Shares of MXCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MXCT stock can currently be purchased for approximately $4.83.

MaxCyte (NASDAQ:MXCT) has a market capitalization of $490.44 million and generates $33.89 million in revenue each year. The company earns $-19.08 million in net income (profit) each year or ($0.170010) on an earnings per share basis.

MaxCyte employs 84 workers across the globe.

MaxCyte's mailing address is 22 FIRSTFIELD ROAD SUITE 110, GAITHERSBURG MD, 20878. The official website for MaxCyte is maxcyte.com. The company can be reached via phone at 301 944 1700, via email at [email protected], or via fax at 301-944-1703.